Alvin F Wells1, Maria Greenwald2, John D Bradley3, Jahangir Alam3, Vipin Arora3, Cynthia E Kartman4. 1. Rheumatology and Immunotherapy Center, Franklin, WI, USA. 2. Desert Medical Advances, Palm Desert, CA, USA. 3. Eli Lilly and Company, Indianapolis, IN, USA. 4. Eli Lilly and Company, Indianapolis, IN, USA. kartman_cynthia@lilly.com.
Abstract
INTRODUCTION: This article evaluates the efficacy and safety of baricitinib 4 mg versus placebo in United States including Puerto Rico (US) and rest of the world (ROW) subpopulations using data pooled from RA-BEAM and RA-BUILD, which enrolled patients with moderate-to-severe adult-onset rheumatoid arthritis (RA). METHODS: In RA-BEAM, patients with an inadequate response (IR) to methotrexate, at least one X-ray erosion, and high sensitivity C-reactive protein (hsCRP) ≥ 6 mg/L were randomized to placebo or orally administered baricitinib 4 mg daily or subcutaneously administered adalimumab 40 mg every other week. In RA-BUILD, patients with an IR to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and with hsCRP ≥ 3.6 mg/L were randomized to placebo or baricitinib 2 or 4 mg daily. Patients in both trials were biologic naive. In this post hoc analysis, data from both studies were pooled (714 baricitinib 4 mg-treated, 716 placebo-treated patients). RESULTS: Overall, 188 US and 1242 ROW patients were included. Subgroups differed in baseline characteristics including race, weight, age, time since RA diagnosis, current corticosteroid use, and previous csDMARD use. At weeks 12 and 24, baricitinib-treated patients had larger responses compared to placebo-treated patients for multiple efficacy outcomes: American College of Rheumatology 20/50/70 response, low disease activity, remission, Disease Activity Score 28-C-reactive protein, and Health Assessment Questionnaire-Disability Index. Overall, similar efficacy was observed in US and ROW subgroups with no notable safety differences between subgroups at weeks 12 or 24. CONCLUSION: Baricitinib 4 mg was efficacious compared to placebo in US and ROW subpopulations. Safety was similar between subgroups. FUNDING: Eli Lilly & Company and Incyte Corporation. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT01721057; NCT01710358.
RCT Entities:
INTRODUCTION: This article evaluates the efficacy and safety of baricitinib 4 mg versus placebo in United States including Puerto Rico (US) and rest of the world (ROW) subpopulations using data pooled from RA-BEAM and RA-BUILD, which enrolled patients with moderate-to-severe adult-onset rheumatoid arthritis (RA). METHODS: In RA-BEAM, patients with an inadequate response (IR) to methotrexate, at least one X-ray erosion, and high sensitivity C-reactive protein (hsCRP) ≥ 6 mg/L were randomized to placebo or orally administered baricitinib 4 mg daily or subcutaneously administered adalimumab 40 mg every other week. In RA-BUILD, patients with an IR to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and with hsCRP ≥ 3.6 mg/L were randomized to placebo or baricitinib 2 or 4 mg daily. Patients in both trials were biologic naive. In this post hoc analysis, data from both studies were pooled (714 baricitinib 4 mg-treated, 716 placebo-treated patients). RESULTS: Overall, 188 US and 1242 ROW patients were included. Subgroups differed in baseline characteristics including race, weight, age, time since RA diagnosis, current corticosteroid use, and previous csDMARD use. At weeks 12 and 24, baricitinib-treated patients had larger responses compared to placebo-treated patients for multiple efficacy outcomes: American College of Rheumatology 20/50/70 response, low disease activity, remission, Disease Activity Score 28-C-reactive protein, and Health Assessment Questionnaire-Disability Index. Overall, similar efficacy was observed in US and ROW subgroups with no notable safety differences between subgroups at weeks 12 or 24. CONCLUSION:Baricitinib 4 mg was efficacious compared to placebo in US and ROW subpopulations. Safety was similar between subgroups. FUNDING: Eli Lilly & Company and Incyte Corporation. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT01721057; NCT01710358.
Entities:
Keywords:
Baricitinib; Clinical Trial; Rheumatoid Arthritis; United States
Authors: Sebastián E Ibáñez Vodnizza; Michael T Nurmohamed; Ingrid M Visman; J Christiaan van Denderen; Willem F Lems; Francisca Jaime; Irene E van der Horst-Bruinsma Journal: J Rheumatol Date: 2017-07-15 Impact factor: 4.666
Authors: Peter C Taylor; Edward C Keystone; Désirée van der Heijde; Michael E Weinblatt; Liliana Del Carmen Morales; Jaime Reyes Gonzaga; Sergey Yakushin; Taeko Ishii; Kahaku Emoto; Scott Beattie; Vipin Arora; Carol Gaich; Terence Rooney; Douglas Schlichting; William L Macias; Stephanie de Bono; Yoshiya Tanaka Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell Journal: Rheumatology (Oxford) Date: 2003-02 Impact factor: 7.580
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Jeremy Sokolove; Michael Schiff; Roy Fleischmann; Michael E Weinblatt; Sean E Connolly; Alyssa Johnsen; Jin Zhu; Michael A Maldonado; Salil Patel; William H Robinson Journal: Ann Rheum Dis Date: 2015-09-10 Impact factor: 19.103